ucc home | site map | Site Feedback
Study at UCC | Current Students | Research | Staff | Teaching & Learning | Visitors | Alumni | About UCC

Media

 

International Academy of Cardiology: Prof Noel M. Caplice, M.D., Ph.D.: THE ROLE OF PROGENITOR CELLS

 

 

 

UCC team develops medical device alternative to open-heart surgery

 

 (Report courtesy of the 12:30 news on TV3)

 

The University College Cork (UCC) Centre for Research in Vascular Biology has developed a medical device that promotes the bypass of arterial obstructions, potentially removing the need for open-heart surgery.

Director of the centre Prof Noel Caplice, himself a practising interventional cardiologist, led the research project in UCC, which included collaborators in the Mayo Clinic in the US.

Caplice began this project in the Mayo Clinic, where he and his colleagues designed a mesh device that could be attached to a stent, which could deliver millions of cells and promote bypass in an obstructed artery.

Since his return to UCC in 2005, Caplice has further developed this technology so it can be delivered using a catheter.

The vascular cell delivery device can be inserted via a keyhole procedure through the artery to the site of the obstruction. The implanted device can then promote micro-bypass of the obstruction over a four-week period, resulting in the return of normal heart function and a recovery of full exercise capacity.

The device has been tested successfully in a large animal model with similar-sized arteries to humans, and the next phase of this research will involve testing on patients who require bypass surgery but have been deemed unfit to undergo the procedure.

About 3m open-heart coronary bypass and peripheral artery bypass operations are carried out each year around the world. However, around 20pc of patients who need this surgery are unable to undergo the procedure due to poor status of arteries or a co-existing illness making the risk too great.

“If reproduced in humans, this device would offer an alternative to open surgical bypass operations with implications for treatment of patients who are currently inoperable,” said Caplice.

“It also has the potential to reduce costs and time spent in hospital,” he added.

This research, which could be a major step forward in the treatment of coronary disease, has been published in the journal Biomaterials.

 

Listen to an interview with Prof Noel Caplice broadcast on the 25th of August 2014 on RTE Radio One's Morning Ireland.

Further media coverage is available on here on Storify.

 

 

UCC Researchers Make Heart Injection Breakthrough 08.06.2011

 

   

 

Heart attack victims could have their damaged hearts repaired by a single injection, which was developed by Cork researchers. The world-leading research by two University College Cork professors could improve the quality and length of lives of people who have suffered heart attacks.

 

Around 15% of people who suffer heart attacks have severe ongoing difficulties because of lasting damage to the heart muscle. This often results in patients suffering further attacks and can ultimately cause heart failure. UCC Professor Noel Caplice, chair of cardiovascular sciences, and Professor Rosemary O’Connor, head of the Department of Biochemistry, have developed a single dose of insulin-like growth factor which is injected into the heart to repair damage to the muscle.

The growth factor has been successfully tested on animals and a clinical trial on patients is expected to start in August.Within three years it could be widely available to patients. Professor Caplice said: “The big thing here is that this is world-leading research taking place here in Cork. “The research has been recognized and won a top award in America and if the trials are successful it will ultimately improve the quality and length of life of a patient who has suffered a heart attack. “It will also be financially beneficial to the health service by removing ongoing care costs. After the injection, which would need to be delivered within 12 hours of a heart attack, the muscle can return to near normal levels within two months.

Professor Caplice was in Dublin today to collect a €1m funding grant under the Translational Research Award programme, run by the Health Research Board and Science Foundation Ireland. “This is a big vote of confidence in the project,” he said. Minister for Research and Innovation Seán Sherlock, who attended the awards, said: “The focus is on bringing scientific researchers and clinicians closer together to deliver health benefits to patients. This can be achieved by converting research findings into innovative strategies, products or services.

Article courtesy of Breaking News.

 
RTE Report on New Heart Muscle Therapy Developed at CRVB 08.04.2011

Top Prize won by CRVB Investigator at American Cardiology Meeting 06.04.2011

 

Dr John O’Sullivan (in photo) from CRVB won the Young Investigator Award at the American College of Cardiology (ACC) Meeting in New Orleans this week.

This ACC meeting is one of the largest of its kind in heart disease in the world and the Young Investigator competes in open international competition with the best cardiac research projects from around the globe. The work presented at the meeting described for the first time the dramatic effects of a single low dose of insulin like growth factor (IGF1) on heart muscle recovery after a large heart attack in an experimental model. More than a million people each year develop heart failure after large heart attacks despite the best currently available therapy. Congratulations John.